August 7, 2025

expert reaction to press release from Lilly about its oral GLP-1, orforglipron, and weight loss, from a phase 3 trials in adults with obesity

Scientists comment on oral GLP-1 (Orforglipron) and weight loss from a phase 3 clinical trial.

Dr Simon Cork, Senior Lecturer in Physiology, Anglia Ruskin University, said:

“These preliminary results on the effectiveness of orforglipron in promoting clinically significant weight loss are a positive step forward in the development of these class of drugs.

“It should be noted that their effects on weight loss are not as profound as that seen in injectable GLP-1 receptor agonists, such as Wegovy, with a lower percentage weight loss and fewer people achieving 10% weight loss at the highest dose.

“Nevertheless, that this medication is an oral form, rather than injectable, will likely be seen as more tolerable for many patients.  The manufacturing costs are also anticipated to be significantly lower than injectable drugs, meaning these medications may be more equitable in their availability.

“It should be noted that these are preliminary, non-peer reviewed results and we will need to see the full trial methodology and data before a more comprehensive analysis can be undertaken.”

Lilly press release: https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivers-weight-loss-average-273

Declared interests

Dr Simon Cork: “No CoI to declare.”